The effect of gadodiamide on cancer cell lines

The effect of gadodiamide on cancer cell lines

Aim: Recent literature suggests that some human cancer cell lines possess a calcium cation receptor. Human myeloma cell lines have demonstrated stimulated cell proliferation by the gadolinium cation through this receptor, and osteosarcoma cell lines possess the same cation receptor. Although enhance...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2009
Автори: Fujimoto, T., Finnegan, M.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2009
Назва видання:Experimental Oncology
Теми:
Short communications
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/138133
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:The effect of gadodiamide on cancer cell lines / T. Fujimoto, M. Finnegan // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 185-187. — Бібліогр.: 13 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-138133
record_format dspace
spelling irk-123456789-1381332018-06-19T03:02:51Z The effect of gadodiamide on cancer cell lines Fujimoto, T. Finnegan, M. Short communications Aim: Recent literature suggests that some human cancer cell lines possess a calcium cation receptor. Human myeloma cell lines have demonstrated stimulated cell proliferation by the gadolinium cation through this receptor, and osteosarcoma cell lines possess the same cation receptor. Although enhanced MRI is a very useful diagnostic tool for the treatment of sarcoma in the orthopedic area, incorporating the use of MRI contrast agents based on gadolinium raises the possibility of the stimulation of cancer cell growth. Methods: Human myeloma (RPMI 8226), osteosarcoma (Saos-2) and rat osteosarcoma (UMR-106) cell lines were exposed to various concentrations of common MRI contrast agent gadodiamide (Omniscan®) (5 μM, 50 μM, 500 μM, 5 mM, 50 mM) in a culture medium. The response of the cells was then assessed by measuring cell proliferation and DNA synthesis. Results: Treatment with 5 μM to 5 mM gadodiamide did not stimulate cell proliferation; only cells exposed to 50 mM gadodiamide showed suppressed proliferation rates. Conclusions: Since intravenously injected gadodiamide is diluted from 500 μM to 1 mM by patient blood flow at enhanced MRI examinations, the results of the present study suggest that gadodiamide has not effect on these types of cancer cells. 2009 Article The effect of gadodiamide on cancer cell lines / T. Fujimoto, M. Finnegan // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 185-187. — Бібліогр.: 13 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/138133 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Short communications
Short communications
spellingShingle Short communications
Short communications
Fujimoto, T.
Finnegan, M.
The effect of gadodiamide on cancer cell lines
Experimental Oncology
description Aim: Recent literature suggests that some human cancer cell lines possess a calcium cation receptor. Human myeloma cell lines have demonstrated stimulated cell proliferation by the gadolinium cation through this receptor, and osteosarcoma cell lines possess the same cation receptor. Although enhanced MRI is a very useful diagnostic tool for the treatment of sarcoma in the orthopedic area, incorporating the use of MRI contrast agents based on gadolinium raises the possibility of the stimulation of cancer cell growth. Methods: Human myeloma (RPMI 8226), osteosarcoma (Saos-2) and rat osteosarcoma (UMR-106) cell lines were exposed to various concentrations of common MRI contrast agent gadodiamide (Omniscan®) (5 μM, 50 μM, 500 μM, 5 mM, 50 mM) in a culture medium. The response of the cells was then assessed by measuring cell proliferation and DNA synthesis. Results: Treatment with 5 μM to 5 mM gadodiamide did not stimulate cell proliferation; only cells exposed to 50 mM gadodiamide showed suppressed proliferation rates. Conclusions: Since intravenously injected gadodiamide is diluted from 500 μM to 1 mM by patient blood flow at enhanced MRI examinations, the results of the present study suggest that gadodiamide has not effect on these types of cancer cells.
format Article
author Fujimoto, T.
Finnegan, M.
author_facet Fujimoto, T.
Finnegan, M.
author_sort Fujimoto, T.
title The effect of gadodiamide on cancer cell lines
title_short The effect of gadodiamide on cancer cell lines
title_full The effect of gadodiamide on cancer cell lines
title_fullStr The effect of gadodiamide on cancer cell lines
title_full_unstemmed The effect of gadodiamide on cancer cell lines
title_sort effect of gadodiamide on cancer cell lines
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2009
topic_facet Short communications
url http://dspace.nbuv.gov.ua/handle/123456789/138133
citation_txt The effect of gadodiamide on cancer cell lines / T. Fujimoto, M. Finnegan // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 185-187. — Бібліогр.: 13 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT fujimotot theeffectofgadodiamideoncancercelllines
AT finneganm theeffectofgadodiamideoncancercelllines
AT fujimotot effectofgadodiamideoncancercelllines
AT finneganm effectofgadodiamideoncancercelllines
first_indexed 2023-10-18T21:17:31Z
last_indexed 2023-10-18T21:17:31Z
_version_ 1796152423406895104

Схожі ресурси